Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations
Background
Risk-based breast cancer screening is designed to tailor screening intensity to a person’s individual chance of developing breast cancer. Instead of offering the same schedule to everyone, this approach uses clinical risk factors, family history, breast density, reproductive history, and sometimes genetic information to decide whether a person should have standard mammography or more intensive high-risk screening, such as breast MRI in addition to mammography.
The WISDOM Study was created to test whether risk-based screening could be a practical alternative to annual mammography for women in the United States. This secondary analysis asked an important question: how much does population-based testing for pathogenic variants, or PVs, add to risk stratification compared with clinical risk models alone or clinical models combined with a polygenic risk score?
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.